Gilead and The Future of HIV Therapy

Amongst the hubbub over hepatitis C and the upcoming EASL conference, it can seem as though Gilead Sciences’ very existence hinges on whether or not the company can successfully develop a drug to treat the viral liver disease. That’s not the case. In fact, the massively profitable HIV business remains the critical driver of Gilead’s cash flow over the long-term.
The Street